abeona
therapeutics
announces
leadership
board
transitions
new
york
cleveland
globe
newswire
abeona
therapeutics
nasdaq
abeo
leader
gene
cell
therapy
today
announced
changes
executive
leadership
board
directors
jo√£o
siffert
resigned
positions
ceo
head
research
development
chief
medical
officer
well
member
board
directors
september
september
brian
pereira
stefano
buono
stephen
howell
george
migausky
shawn
tomasello
announced
stepped
board
effective
immediately
director
gave
reason
resignation
director
indicated
disagreements
company
company
reviewing
exploring
strategic
options
alternatives
focused
advancing
company
mission
maximizing
stakeholder
value
including
sale
assets
sale
company
assurance
strategic
review
result
completion
particular
course
action
defined
timeline
completion
review
process
abeona
therapeutics
abeona
therapeutics
biopharmaceutical
company
developing
gene
cell
therapies
serious
diseases
abeona
clinical
programs
include
autologous
cell
therapy
recessive
dystrophic
epidermolysis
bullosa
phase
development
well
novel
gene
therapies
sanfilippo
syndrome
types
b
mps
iiia
mps
iiib
respectively
phase
development
company
portfolio
gene
therapies
also
features
disease
abeona
novel
capsids
shown
potential
improve
tropism
profiles
variety
devastating
diseases
abeona
fully
functional
gene
cell
therapy
gmp
manufacturing
facility
produces
pivotal
phase
study
capable
clinical
commercial
production
gene
therapies
information
visit
statements
press
release
contains
certain
statements
within
meaning
section
securities
act
amended
section
securities
exchange
act
amended
involve
risks
uncertainties
statements
include
statements
company
exploring
strategic
options
including
sale
assets
sale
company
attempted
identify
forward
looking
statements
terminology
may
believe
estimate
expect
similar
expressions
well
words
expressions
referencing
future
events
conditions
circumstances
constitute
intended
identify
statements
actual
results
may
differ
materially
indicated
statements
result
various
important
factors
numerous
risks
uncertainties
including
limited
potential
impacts
pandemic
business
operations
financial
condition
continued
interest
rare
disease
portfolio
ability
enroll
patients
clinical
trials
outcome
future
meetings
food
drug
administration
regulatory
agencies
impact
competition
ability
secure
licenses
technology
may
necessary
commercialize
products
ability
achieve
obtain
necessary
regulatory
approvals
impact
changes
financial
markets
global
economic
conditions
risks
associated
data
analysis
reporting
risks
disclosed
company
recent
annual
report
form
subsequent
quarterly
reports
form
periodic
reports
filed
securities
exchange
commission
company
undertakes
obligation
revise
statements
update
reflect
events
circumstances
occurring
date
presentation
whether
result
new
information
future
developments
otherwise
except
required
federal
securities
laws
